Compare TECH & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | HLN |
|---|---|---|
| Founded | 1976 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | 24622 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 44.5B |
| IPO Year | 1989 | N/A |
| Metric | TECH | HLN |
|---|---|---|
| Price | $59.83 | $10.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 1 |
| Target Price | ★ $71.23 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 9.4M |
| Earning Date | 02-04-2026 | 07-31-2025 |
| Dividend Yield | 0.54% | ★ 1.81% |
| EPS Growth | N/A | ★ 41.64 |
| EPS | ★ 0.49 | 0.23 |
| Revenue | $1,216,732,000.00 | ★ $15,096,588,575.00 |
| Revenue This Year | $2.33 | $1.51 |
| Revenue Next Year | $7.05 | $4.67 |
| P/E Ratio | $122.55 | ★ $21.33 |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $46.01 | $8.71 |
| 52 Week High | $79.28 | $11.42 |
| Indicator | TECH | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 58.70 |
| Support Level | $58.54 | $10.05 |
| Resistance Level | $59.64 | $10.15 |
| Average True Range (ATR) | 1.46 | 0.11 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 80.40 | 76.15 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.